In an established murine model of diabetic nephropathy (ApoE−/− mice), setanaxib protected against the development of albuminuria, glomerulosclerosis and mesangial expansion, while significantly decreasing the diabetes‐induced expression of glomerular VEGF, collagen IV and fibronectin in ApoE−/− mice compared with non‐treated ApoE−/− mice.21, 24. Here, VEGFA is linked to glomerulosclerosis.